The Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA recommended the approval of the Praluent Injection after the bell Tuesday. The Committee voted 13 to three that Regeneron Pharmaceuticals Inc. (REGN) and Sanofi had sufficiently established that the low-density lipoprotein cholesterol lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.
Regeneron Pharmaceuticals was halted throughout Tuesday's trading session. The stock is now down 17.52 on 9K shares after the close.
For comments and feedback contact: editorial@rttnews.com
Business News